Alabama Hemp Regulation Bill HB 445 Faces Opposition Over Safety and Economic Concerns

On April 2, 2025, the Alabama House Health Committee convened to discuss critical issues surrounding the regulation of hemp-derived products, particularly focusing on the growing concerns about THC gummies and vapes in schools. The meeting highlighted the urgent need for effective legislation to address the rising prevalence of these substances among minors, with testimonies from various stakeholders emphasizing both the dangers and the economic implications of proposed regulations.

Christine Carr, a nurse anesthetist with extensive experience in drug prevention, voiced strong support for the committee's efforts to regulate THC levels in hemp products. She underscored the importance of testing for potency at the end product stage, advocating for amendments to ensure that products remain compliant with the legal THC limit of 0.3%. Carr's testimony reflected a broader concern about the accessibility of high-potency products to minors, which she described as a pressing public health issue.

Conversely, several industry representatives expressed opposition to the proposed legislation, specifically House Bill 445. They argued that the bill's restrictions could inadvertently harm legal businesses and limit consumer choices. Molly Cole, representing the Alabama Hemp and Vape Association, cautioned against rushed legislation that could jeopardize over 10,000 jobs in the state. She called for a more coordinated approach to regulation, emphasizing the need for responsible oversight rather than punitive measures that could push consumers to neighboring states.

Becky Garretson, Executive Director of Eagle Fordmouth Alabama, raised concerns about the bill's potential to inadvertently legalize psychoactive cannabinoids, which she argued could lead to a de facto legalization of recreational marijuana in Alabama. Her testimony highlighted the complexities of distinguishing between psychoactive and non-psychoactive products, calling for stricter bans on the former.

The committee's discussions also touched on the enforcement challenges posed by the proposed regulations, with questions about who would oversee compliance and the costs associated with such oversight remaining largely unanswered. Stakeholders urged the committee to consider a study commission to develop evidence-based policies that would effectively balance public safety with economic interests.

In conclusion, the Alabama House Health Committee's meeting underscored the urgent need for thoughtful regulation of hemp-derived products in the state. As the discussions continue, the challenge remains to craft legislation that protects minors while also supporting responsible adult use and the economic viability of the hemp industry. The committee's next steps will be crucial in determining how Alabama navigates this complex issue.